ReviewMicrobial biotechnology2022
Use of CRISPR-Cas tools to engineer Trichoderma species.
Review in Microbial biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 49 citations in OpenAlex.
- Mechanisms of action and biocontrol potential ofFrontiers in fungal biology · 2026Review
- EngineeringAIMS microbiology · 2026Review
- Biocontrol Strategies Against Plant-Parasitic Nematodes UsingJournal of fungi (Basel, Switzerland) · 2025Review
- Synthetic Biology in Natural Product Biosynthesis.Chemical reviews · 2025Review
- Mechanisms and impacts of Agaricus urinascens fairy rings on plant diversity and microbial communities in a montane Mediterranean grassland.FEMS microbiology ecology · 2025Article
- Simply cut out - Combining CRISPR/Cas9 RNPs and transiently selected telomere vectors for marker free-gene deletion inFrontiers in genome editing · 2025Article
- A comparative assessment of microbial biodiesel and its life cycle analysis.Folia microbiologica · 2024Review
- Development of the thermophilic fungus Myceliophthora thermophila into glucoamylase hyperproduction system via the metabolic engineering using improved AsCas12a variants.Microbial cell factories · 2023Article
- Strategies for the Development of Industrial Fungal Producing Strains.Journal of fungi (Basel, Switzerland) · 2023Review
- Exploiting synergies between microbial electrochemical technologies and synthetic biology.Microbial biotechnology · 2023Article
- Molecular Approaches for Detection ofBiology · 2023Review
- Review
- Application progress of CRISPR/Cas9 genome-editing technology in edible fungi.Frontiers in microbiology · 2023Review
- Establishment, optimization, and application of genetic technology inFrontiers in microbiology · 2023Review
- Use of CRISPR-Cas tools to engineer Trichoderma species.Microbial biotechnology · 2022Review
- A Simple and Efficient CRISPR/Cas9 System Using a Ribonucleoprotein Method forJournal of fungi (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Given their lignocellulose degradability and biocontrol activities, fungi of the ubiquitously distributed genus Trichoderma have multiple industrial and agricultural applications. Genetic manipulation plays a valuable role in tailoring novel engineered strains with enhanced target traits. Nevertheless, as applied to fungi, the classic tools of genetic manipulation tend to be time-consuming and tedious. However, the recent development of the CRISPR-Cas system for gene editing has enabled researchers to achieve genome-wide gene disruptions, gene replacements, and precise editing, and this technology has emerged as a primary focus for novel developments in engineered strains of Trichoderma. Here, we provide a brief overview of the traditional approaches to genetic manipulation, the different strategies employed in establishing CRSIPR-Cas systems, the utilization of these systems to develop engineered strains of Trichoderma for desired applications, and the future trends in biotechnology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.